Pharma Pioneer

RECCE® 327 Phase I/II Trial Advances with Next Dosage Cohort for UTIs and Urosepsis

19 May 2024
2 min read

Recce Pharmaceuticals Ltd, a company focused on developing synthetic anti-infectives to combat antibiotic resistance and emerging viral threats, has initiated a new phase in its clinical trials. The latest group of participants in the Phase I/II study received a 3,000mg dose of the company's lead product, RECCE® 327 (R327), in a rapid 20-minute infusion. This dosage is part of a broader strategy to test various infusion times, including 15, 30, 45 minutes, and 1 hour, to determine the optimal therapeutic window for R327.

The company's CEO, James Graham, expressed optimism about the drug's potential, noting its demonstrated safety and effectiveness against a wide array of antibiotic-resistant pathogens. He highlighted the drug's topical application in treating diabetic foot ulcer infections and the promising safety profile for treating urinary tract infections (UTIs) and urosepsis, which affect millions globally.

Recce Pharmaceuticals is also exploring R327's intravenous administration, with the results expected upon the trial's conclusion. The trial is registered with the Australia New Zealand Clinical Trial Registry under the ID ACTRN12623000448640.

The company's anti-infective pipeline comprises three patented synthetic polymers, including R327 for serious bacterial infections, RECCE® 435 for oral bacterial infections, and RECCE® 529 for viral infections. These anti-infectives are designed with multi-layered mechanisms to counteract the rapid mutation rates of bacteria and viruses, a challenge that current antibiotics struggle with.

RECCE® 327 has received the Qualified Infectious Disease Product designation from the FDA under the GAIN Act, which includes a Fast Track Designation and a 10-year market exclusivity post-approval. It is also recognized as the sole synthetic polymer and sepsis drug candidate in development by The Pew Charitable Trusts Global New Antibiotics in Development Pipeline. However, R327 is not yet approved for human use and requires further clinical trials to assess its safety and efficacy fully.

Recce Pharmaceuticals maintains full ownership of its automated manufacturing process, which is instrumental in supporting ongoing clinical trials. The company's mission is to leverage its technological capabilities to address critical medical needs and develop innovative anti-infective treatments.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Promising Early Results from NXP800 Trial in Treating Platinum-Resistant Ovarian Cancer
Pharma Pioneer
2 min read
Promising Early Results from NXP800 Trial in Treating Platinum-Resistant Ovarian Cancer
19 May 2024
Preliminary results from a Phase 1b clinical trial of the drug NXP800, developed by Nuvectis Pharma, Inc., have shown promising signs in the treatment of platinum-resistant ARID1a-mutated ovarian cancer.
Read →
NUV-1511 Phase 1/2 Trial Begins with First Patient Dosing for Advanced Tumor Treatment
Pharma Pioneer
2 min read
NUV-1511 Phase 1/2 Trial Begins with First Patient Dosing for Advanced Tumor Treatment
19 May 2024
Nuvation Bio has initiated clinical trials for its first drug-drug conjugate (DDC), NUV-1511.
Read →
New Human Data Reinforces CAN10's Potential for Treating Systemic Sclerosis
Pharma Pioneer
3 min read
New Human Data Reinforces CAN10's Potential for Treating Systemic Sclerosis
19 May 2024
The company's research has discovered that the cytokines targeted by CAN10, namely IL-1, IL-33, and IL-36, are significantly elevated in the skin samples of systemic sclerosis patients.
Read →
Lantern Pharma Initiates Human Trials with AI-Driven Drug Candidate LP-284
Pharma Pioneer
3 min read
Lantern Pharma Initiates Human Trials with AI-Driven Drug Candidate LP-284
19 May 2024
Lantern Pharma's AI-driven drug candidate, LP-284, has entered a Phase 1 clinical trial, marking a significant step in the fight against cancer.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.